← All trials
NCT01370291
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jun 30, 2011
- Primary completion
- Dec 31, 2012
- Completion date
- Dec 31, 2013
- First posted
- Jun 9, 2011
- Last posted
- Feb 15, 2012
- Enrollment
- 60
- Arms / groups
- 3 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Xijing HospitalLead sponsor
- Xijing HospitalReponsible party - principal investigator
- Xijing HospitalSponsor investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.